HDV vs XBI
iShares Core High Dividend ETF vs SPDR S&P Biotech ETF
- • HDV has the lower expense ratio at 0.08% vs 0.35% for XBI.
- • HDV pays a higher dividend yield (2.90%).
Side-by-side metrics
| Metric | HDV | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.08% | 0.35% |
Dividend yield Trailing 12-month yield. | 2.90% | 0.36% |
AUM Assets under management — bigger funds are typically more liquid. | $13.66B | $10.73B |
YTD return | 16.00% | 33.79% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.32 | 1.10 |
P/E ratio | 21.92 | — |
Last price | $27.58 | $164.28 |
Inception | — | — |
Issuer | iShares | State Street |
HDV top holdings
| XOM | Exxon Mobil Corp | 7.26% |
| ABBV | AbbVie Inc | 6.48% |
| CVX | Chevron Corp | 5.41% |
| VZ | Verizon Communications Inc | 5.23% |
| HD | The Home Depot Inc | 4.96% |
| PG | Procter & Gamble Co | 4.81% |
| PM | Philip Morris International Inc | 4.42% |
| PFE | Pfizer Inc | 4.31% |
| MRK | Merck & Co Inc | 4.12% |
| KO | Coca-Cola Co | 3.98% |
XBI top holdings
| APGE | Apogee Therapeutics Inc | 1.49% |
| MRNA | Moderna Inc | 1.41% |
| TWST | Twist Bioscience Corp | 1.41% |
| ORKA | Oruka Therapeutics Inc | 1.38% |
| KYMR | Kymera Therapeutics Inc Ordinary Shares | 1.36% |
| VKTX | Viking Therapeutics Inc | 1.30% |
| PRAX | Praxis Precision Medicines Inc Ordinary Shares | 1.29% |
| ERAS | Erasca Inc | 1.27% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.20% |
| RYTM | Rhythm Pharmaceuticals Inc | 1.20% |
About HDV
HDV (iShares Core High Dividend ETF) is US high-dividend stocks with quality screen. Managed by iShares, the fund carries $13.7B in assets under management, an expense ratio of 0.08%, a dividend yield of 2.90%. Its largest holding is Exxon Mobil Corp (XOM), which represents 7.3% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 9.3%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.36%. Its largest holding is Apogee Therapeutics Inc (APGE), which represents 1.5% of the portfolio. Financial Services is the fund's largest sector exposure at 0.5%.